2025 India Autoimmune Disease Treatment Market Revenue Opportunities Report
Description
The 2025 India Autoimmune Disease Treatment Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autoimmune Disease Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the autoimmune disease treatment market in India are Biocon, AbbVie Inc., Johnson & Johnson, and Amgen. Biocon, India’s leading biopharmaceutical company, focuses on affordable biologics and biosimilars for autoimmune diseases and has innovated in novel immunotherapies, including CAR-T cell therapies for cancer and autoimmune disorders within India. AbbVie and Johnson & Johnson are global leaders with significant market shares—16.6% and 11.4% respectively—in autoimmune disease therapeutics globally and India is a growing market for their biologic and immunosuppressive drugs. Johnson & Johnson recently received FDA breakthrough therapy designation for nipocalimab, targeting Sjögren’s disease, highlighting its advanced research pipeline relevant to India’s market.
Amgen, an American multinational biopharma company, is also a key player with a strong portfolio targeting autoimmune conditions like psoriasis and rheumatoid arthritis using biologics such as Enbrel (Etanercept). These companies are contributing to the Indian market’s growth, driven by rising autoimmune cases, increased healthcare awareness, and regulatory support for novel therapies, which is projected to grow at a CAGR of about 5.6% in India. Their active participation includes localized manufacturing, clinical trials, and strategic investments to improve access and affordability of advanced autoimmune treatments in India.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autoimmune Disease Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the autoimmune disease treatment market in India are Biocon, AbbVie Inc., Johnson & Johnson, and Amgen. Biocon, India’s leading biopharmaceutical company, focuses on affordable biologics and biosimilars for autoimmune diseases and has innovated in novel immunotherapies, including CAR-T cell therapies for cancer and autoimmune disorders within India. AbbVie and Johnson & Johnson are global leaders with significant market shares—16.6% and 11.4% respectively—in autoimmune disease therapeutics globally and India is a growing market for their biologic and immunosuppressive drugs. Johnson & Johnson recently received FDA breakthrough therapy designation for nipocalimab, targeting Sjögren’s disease, highlighting its advanced research pipeline relevant to India’s market.
Amgen, an American multinational biopharma company, is also a key player with a strong portfolio targeting autoimmune conditions like psoriasis and rheumatoid arthritis using biologics such as Enbrel (Etanercept). These companies are contributing to the Indian market’s growth, driven by rising autoimmune cases, increased healthcare awareness, and regulatory support for novel therapies, which is projected to grow at a CAGR of about 5.6% in India. Their active participation includes localized manufacturing, clinical trials, and strategic investments to improve access and affordability of advanced autoimmune treatments in India.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
